170 related articles for article (PubMed ID: 37591782)
1. Toremifene, an Alternative Adjuvant Endocrine Therapy, Is Better Than Tamoxifen in Breast Cancer Patients with CYP2D6*10 Mutant Genotypes.
Li X; Li Z; Li L; Liu T; Qian C; Ren Y; Li Z; Chen K; Ji D; Zhang M; Wang J
Cancer Res Treat; 2024 Jan; 56(1):134-142. PubMed ID: 37591782
[TBL] [Abstract][Full Text] [Related]
2. Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen.
Wang H; Ma X; Zhang B; Zhang Y; Han N; Wei L; Sun C; Sun S; Zeng X; Guo H; Li Y; Zhang Y; Zhao J; Qin Z; Liu Z; Zhang N
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e148-e153. PubMed ID: 34196110
[TBL] [Abstract][Full Text] [Related]
3. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
4. The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.
Zeng Y; Huang K; Huang W
Pak J Pharm Sci; 2017 May; 30(3(Special)):1095-1098. PubMed ID: 28671087
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
[TBL] [Abstract][Full Text] [Related]
9. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
12. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study.
Gu R; Jia W; Zeng Y; Rao N; Hu Y; Li S; Wu J; Jin L; Chen L; Long M; Chen K; Chen L; Xiao Q; Wu M; Song E; Su F
BMC Cancer; 2012 May; 12():161. PubMed ID: 22548922
[TBL] [Abstract][Full Text] [Related]
13. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
Ismail Al-Khalil W; Al-Salhi L; Rijjal S; Aljamali M; Youssef LA
BMC Cancer; 2022 Oct; 22(1):1067. PubMed ID: 36243690
[TBL] [Abstract][Full Text] [Related]
14. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
15. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials.
Zhou WB; Ding Q; Chen L; Liu XA; Wang S
Breast Cancer Res Treat; 2011 Aug; 128(3):625-31. PubMed ID: 21553116
[TBL] [Abstract][Full Text] [Related]
16. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
Toyama T; Yamashita H; Sugiura H; Kondo N; Iwase H; Fujii Y
Jpn J Clin Oncol; 2009 Oct; 39(10):651-6. PubMed ID: 19596663
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
20. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]